PT - JOURNAL ARTICLE AU - Cassandra R. Harapas AU - Kim S. Robinson AU - Kenneth Lay AU - Jasmine Wong AU - Ricardo Moreno Traspas AU - Nasrin Nabavizadeh AU - Annick Raas-Rothschild AU - Bertrand Boisson AU - Scott B. Drutman AU - Pawat Laohamonthonkul AU - Devon Bonner AU - Mark Gorrell AU - Sophia Davidson AU - Chien-Hsiung Yu AU - Hulya Kayserili AU - Nevin Hatipoglu AU - Jean-Laurent Casanova AU - Jonathan A. Bernstein AU - Franklin L. Zhong AU - Seth L. Masters AU - Bruno Reversade TI - DPP9 deficiency: an Inflammasomopathy which can be rescued by lowering NLRP1/IL-1 signaling AID - 10.1101/2021.01.31.21250067 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.31.21250067 4099 - http://medrxiv.org/content/early/2021/06/09/2021.01.31.21250067.short 4100 - http://medrxiv.org/content/early/2021/06/09/2021.01.31.21250067.full AB - Dipeptidyl peptidase 9 (DPP9) is a direct inhibitor of NLRP1, but how it impacts inflammasome regulation in vivo is not yet established. Here, we report two families with immune-associated defects, skin pigmentation abnormalities and neurological deficits that segregate with biallelic DPP9 rare variants. Using patient-derived primary cells and biochemical assays, these variants are shown to behave as hypomorphic or loss-of-function alleles that fail to repress NLRP1. Remarkably, the removal in mice, of a single copy of either Nlrp1a/b/c, Asc, Gsdmd, Il-1r, but not Il-18, was sufficient to rescue the lethality of Dpp9 mutant neonates. These experiments suggest that the deleterious consequences of DPP9 deficiency are mostly driven by the aberrant activation of the canonical NLRP1 inflammasome and IL-1β signaling. Collectively, our results delineate a Mendelian disorder of DPP9 deficiency driven by increased NLRP1 activity as demonstrated in patient cells and in a mouse model of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by a Strategic Positioning Fund for Genetic Orphan Diseases and an inaugural A*STAR Investigatorship from the Agency for Science, Technology and Research in Singapore. The Laboratory of Human Genetics of Infectious Diseases is supported by the National Center for Research Resources and the National Center for Advancing Sciences (NCATS) of the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (UL1TR001866), the French National Research Agency (ANR) under the Investments for the Future ANR program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the PNEUMOPID project (Grant ANR 14-CE15-0009-01), the French Foundation for Medical Research (FRM) (EQU201903007798), the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, Institut National de la Sante et de la Recherche Medicale (INSERM), and the Universite de Paris. K.L. is supported by a NMRC Open Fund - Young Individual Research Grant (OFYIRG19MAY- 0039).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by A*STAR IRB (2019-087) and genetic analyses were performed in accordance with bioethics rules of national laws. Written informed consents were obtained from all the participants or their parents. The study was approved by and performed in accordance with the requirements of the institutional ethics committees of The Rockefeller University Hospital, New York, USA, and Necker-Enfants Malades Hospital, Paris, France. Informed consent was obtained for all patient and healthy control volunteers reported in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon request.